`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`SAMSUNG BIOEPIS CO., LTD., CELLTRION INC,
`and BIOCON BIOLOGICS INC.
`Petitioners,
`v.
`REGENERON PHARMACEUTICALS, INC.,
` Patent Owner.
`
`Patent No. 11,253,572
`
`Inter Partes Review No. IPR2023-008841
`
`DECLARATION OF JEREMY COBB
`
`1 IPR2024-00260 and IPR2024-00298 are joined with IPR2023-00884.
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2242 Page 1
`
`
`
`
`
`
`IPR2023-00884
`
`
`
`I, Jeremy Cobb, do hereby declare as follows:
`
`1.
`
`I am a member in good standing of the Maryland State Bar (2012) and
`
`the District of Columbia Bar (2013), as well as the following federal court: U.S.
`
`Court of Appeals for the Federal Circuit (2012).
`
`2.
`
`I am a partner at the law firm of Arnold & Porter Kaye Scholer LLP
`
`(“Arnold & Porter”). I began working at Arnold & Porter in October 2021, and prior
`
`to that was an associate at Covington & Burling LLP for nine years.
`
`3.
`
`I am an experienced litigating attorney with over 12 years in private law
`
`practice, and substantial experience with patent litigation. I have been counsel in at
`
`least fifteen patent infringement matters, including in various district courts across
`
`the country, the Patent Trial & Appeal Board, and the Federal Circuit. My patent
`
`litigation experience includes cases related to biologics and small molecules.
`
`4.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`5.
`
`I have never had an application for admission to practice before any
`
`court or administrative body denied.
`
`6.
`
`I have had no sanctions or contempt citations imposed against me by
`
`any court or administrative body.
`
`7.
`
`I have read and will comply with the Office Patent Trial Practice Guide
`
`and the Board’s Rules of Practice for Trials set forth in 37 C.F.R. § 42.
`
`
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2242 Page 2
`
`2
`
`
`
`
`
`
`IPR2023-00884
`
`8.
`
`I agree to be subject to the USPTO Rules of Professional Conduct set
`
`forth in 37 C.F.R. §§ 11.101 et seq. and disciplinary jurisdiction under 37 C.F.R. §
`
`11.19(a).
`
`9.
`
`I have applied to appear pro hac vice in the following other proceedings
`
`before the USPTO: IPR2016-00458, IPR2021-00880, IPR2021-00881, IPR2022-
`
`01225, IPR2022-01226, and IPR2023-00442. The USPTO granted my pro hac vice
`
`application in IPR2016-00458, IPR2021-00880, IPR2021-00881, IPR2022-01225,
`
`IPR2022-01226, and IPR2023-00442.
`
`10. Adam R. Brausa (Reg. No. 60,287) is an experienced registered patent
`
`attorneys with whom I have worked closely and will continue to do so.
`
`11.
`
`I have significant familiarity with the subject matter at issue in this
`
`proceeding and have substantive knowledge of the patent at issue (U.S. Patent No.
`
`11,253,572 (the “’572 Patent”)) by virtue of my preparation for this proceeding. A
`
`significant amount of my time since October 2021 has been spent working on issues
`
`related to the ’572 Patent, related patents, and Patent Owner’s commercial product,
`
`Eylea. Therefore, I have a substantial familiarity with the subject matter of this
`
`proceeding.
`
`
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2242 Page 3
`
`3
`
`
`
`
`
`
`IPR2023-00884
`
`12.
`
`In addition, I have a Bachelor’s of Science degree in chemistry from
`
`Butler University, a Master’s degree in organic chemistry from the University of
`
`Illinois-Urbana Champaign, and I worked in the pharmaceutical industry as a
`
`research scientist for five years.
`
`13.
`
`I hereby declare under penalty of perjury under the laws of the United
`
`States of America that the foregoing is true and correct, and that all statements made
`
`of my own knowledge are true and that all statements made on information and belief
`
`are believed to be true. I understand that willful false statements are punishable by
`
`fine or imprisonment or both. See 18 U.S.C. § 1001.
`
`Dated: March 13, 2024
`
`/Jeremy Cobb/
`Jeremy Cobb
`
`
`
`
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2242 Page 4
`
`4
`
`